Celgene gets European nod for Abraxane in pancreatic cancer; Sinclair buys Obvieline Labs for its Perfectha derm gel;

@FiercePharma: Move over, BigPharma. Valeant's CEO plans to elbow his way in. More | Follow @FiercePharma

@EricPFierce: China clears vaccinemakers in deaths then shuts some down. Story | Follow @EricPFierce

@CarlyHFierce: Hi-Tech Pharmacal CEO to reap almost $85M from its sale to Akorn. Article | Follow @CarlyHFierce

> Celgene's ($CELG) Abraxane won a new indication in Europe as a first-line treatment for patients with metastatic pancreatic cancer. Release

> Sinclair IS Pharma acquired global rights to a dermatology gel, Perfectha, by buying its maker, Obvieline Laboratories. Report

> Mylan ($MYL) bought the rights to a respiratory drug from Pfizer ($PFE) and says the product is ready to submit to the FDA for approval. Report

> Poor people with diabetes are more likely to go to the hospital with low blood sugar when their food budgets are tight, a study found. Report (sub. req.)

Medical Device News

@FierceMedDev: BD trades $40M for diagnostics partner Alverix. More | Follow @FierceMedDev

@MichaelGFierce: How a single nanoparticle delivers two drugs separately to kill cancer cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: The FDA warns Abbott's faulty blood glucose test strips could lead to serious injury or death. Story | Follow @GalenMoore

> Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device. Item

> Stryker teams with Samsung's NeuroLogica on a portable CT scanner. More

> FDA slaps its most serious label on Abbott's diabetes recall. Article

> Medtronic spends $160M on Tyrx and its antibacterial envelopes. News

Biotech News

@FierceBiotech: Texas' Bellicum gets $15M to expand work on gene 'switch' tech. More | Follow @FierceBiotech

@JohnCFierce: In search for success, R&D teams are overcrowding small drug franchises. Story | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: Alcohol-addicted rats treated with optogenetics stop drinking. More from FierceBiotech Research | Follow @EmilyMFierce

> Epizyme shares rocket up on news of $29M milestone awards. More

> Neurocrine shares soar with a promising second take on a PhIIb drug. Story

> Lilly is carving up to $1B out of its struggling R&D division. News

Biotech Research News

> Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer. More

> 6 U.S. institutions receive $540M in cancer research funds. Story

> Astellas, ClearPath team up to develop vaccines for infectious diseases. Article

> Gene defect that blocks insulin release in mice may cause Type 2 diabetes. News

> Alcohol-addicted rats treated with optogenetics stop drinking. Report

> Discovery of immune boosters' role in TB control could help develop new therapeutics. Item

Pharma Manufacturing News

> $1B deal pushes GE further into biologics manufacturing. More

> Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences. Article

> Chinese heparin maker Hepalink buying U.S.-based SPL. Story

> China clears vaccine makers in deaths then shuts some down. News

> EMA makes inspection reports public. Item

> Baxter issues another recall after particulate found in products. Report

And Finally... A study found that meditation can deliver small improvements in anxiety and depression. Report

 

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.